Restricted accessLetterFirst published online 2025-10
Response to the letter by Uysal Tan and Tan regarding our article “short- and mid-term efficacy of sacral neuromodulation in the treatment of neurogenic overactive bladder in patients with multiple sclerosis”
PhéVChartier-KastlerEPanickerJN.Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol2016; 13: 275–288.
2.
GoudelockeCXavierKPechaB, et al. Evaluation of clinical performance and safety for the rechargeable InterStim Micro device in overactive bladder subjects: 6-month results from the global postmarket ELITE study. Neurourol Urodyn2023; 42: 761–769.
3.
DequirezP-LWachterSDBiardeauX.Sacral neuromodulation for low urinary tract dysfunction: Overview and mechanisms of action. Auton Neurosci Basic Clin2025; 261: 103337.
4.
OlivierLDequirezP-LCarolusB, et al. Short-term efficacy of sacral neuromodulation on cystometric parameters in patients with detrusor overactivity. Neuromodulation. Epub ahead of print 22 August 2025. DOI: 10.1016/j.neurom.2025.06.014.
5.
GroenendijkPMLycklamaàNyeholtAAHeesakkersJP, et al. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int2008; 101(3): 325–329.
6.
BlokBFMGroenJBoschJLHR, et al. Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators. BJU Int2006; 98: 1238–1243.
7.
CruzFHerschornSAliottaP, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial. Eur Urol2011; 60(4): 742–750.
8.
KendallHJKnopsAGerlachO, et al. Sacral neuromodulation in multiple sclerosis: The NEMISIS study. Eur Urol Focus. Epub ahead of print 3 March 2025. DOI: 10.1016/j.euf.2025.02.009.
